Company intelligence / Profile preview
Genbioma Aplicaciones
Navarra, Navarra, Spaingenbioma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Genbioma’s postbiotic pA1cHI has demonstrated significant reduction in HbA1c, body weight, BMI, and fat mass in a randomized, placebo-controlled pilot trial in obese individuals, with larger clinical trials underway for type 2 diabetes. Preclinical studies and early clinical data support efficacy in modulation of metabolic markers and prevention of diabetes progression[5].
- Therapeutic areas
- CardiovascularEndocrinology
- Modalities
- ProbioticPostbioticMicrobial therapyLive biotherapeutic product therapyNutritional ingredient
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
EIT Food AcceleratorHospital Universitario VinalopóSandwalk Bioventures SL
Beyond the preview
Go deeper on Genbioma Aplicaciones.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genbioma Aplicaciones.